MSGS stock to get boost if Knicks can stretch Spurs series to game 6, Guggenheim says

Guggenheim raised Madison Square Garden Sports' price target to $470 from $422 and reiterated a buy rating, citing upside from a possible Knicks Game 6 in the NBA Finals and other catalysts. The firm said an extra Game 6 at Madison Square Garden could add $15 million+ in revenue, while broader valuation work implies a $540-$570 per share trading range versus the current price. The company also beat fiscal Q3 revenue estimates at $432.2 million vs. $429.7 million consensus and is exploring a separation of its Knicks and Rangers businesses.

Analysis

The market is likely underestimating how much of MSGS’ value is now driven by event optionality rather than steady-state team economics. The Finals run creates a near-dated monetization pulse, but the larger lever is that every extra home game or extended series disproportionately boosts high-margin revenue streams, so the earnings sensitivity is convex rather than linear. That means the stock can rerate sharply on incremental good news even if the underlying business quality is already recognized.

The bigger second-order catalyst is structural simplification. A separation would force the market to stop valuing the Knicks and Rangers as a blended asset with governance drag and instead mark each entity closer to sports-franchise comps, where scarcity and control premiums matter more. If the market starts capitalizing the Knicks as a standalone trophy asset with multiple monetization pathways, today’s discount to implied private value could compress over months, not quarters.

The main risk is that the catalyst stack is crowded and event-driven, which makes the tape vulnerable to disappointment or “sell the news” behavior once the series outcome is known. The highest-beta path is that the market is paying for a multi-stage narrative: playoff revenue, spin-off optionality, and expansion windfalls. Any delay or dilution in one of those pieces could flatten the upside quickly, especially if investors decide the expansion payout is too contingent or too far out on the timeline.

Consensus appears to be treating expansion as incremental upside, but the real significance is that it may reset the valuation framework for the franchise as a quasi-capitalized royalty stream on league growth. That is powerful, but also means the stock can overshoot on headline optimism. In that sense, the trade is less about the Finals result alone and more about whether management can convert momentum into a credible separation roadmap before enthusiasm fades.

Key Decisions for Investors

• Long MSGS into the next 1-3 weeks on series-extension probability; best risk/reward is buying on any post-game pullback, with upside driven by convex revenue sensitivity to additional home dates and headline flow.
• Use call spreads on MSGS for the next 1-2 months rather than outright stock if you expect event volatility; this captures rerating toward private-market comp valuation while limiting downside if the series ends early or the stock sells the news.
• Pair trade: long MSGS / short a broad sports-media or live-entertainment basket over 3-6 months, betting that scarcity value and separation optionality are underappreciated relative to more cyclical content names.
• If the spin-off process becomes concrete, add on confirmation and hold for 6-12 months; the highest upside comes from the market repricing the stand-alone Knicks asset, not from the playoff revenue itself.
• Take profits into any sharp pre-announcement strength if the stock approaches the top end of private-value commentary before there is an executable separation plan; upside is real, but the easiest money is likely before consensus fully re-rates the asset.